Summary

The global Drug discovery services market is projected to reach USD 41.3 billion by 2028 from USD 20.6 billion in 2023, at a CAGR of 14.9% during the forecast period of 2023 to 2028. Growing R&D expenditure in pharma-biotech sector, increasing drug R&D pipeline and rising reliance on outsourcing, initiatives for research on rare diseases and orphan drugs, and high cost of in-house drug development are expected to provide growth to the market.

Oncology is expected to account for the largest share for therapeutic area segment
Based on therapeutic are the oncology segment has the largest market share. The list of drugs in development for oncology has increased over the years due to the rising number of clinical trials and the growing R&D expenditure by pharmaceutical companies on oncology-based drugs. The incidence of cancer has increased rapidly across the globe. According to GLOBOCAN, the number of new cases is projected to reach 28.9 million by 2040 from 19.3 million in 2020, at a CAGR of ~2% from 2020 to 2040. Owing to this, companies are increasingly focusing on developing novel medicines for cancer; this is expected to drive the growth of this therapeutic segment.

The Hit-to-lead identification segment accounted for the largest share of the process segment in the drug discovery services market
Based on process, the drug discovery services market is broadly classified into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification segment accounted for the largest share of the drug discovery services market in 2022. Due to its crucial role in the drug discovery process, the hit-to-lead identification is the maximum revenue generating process, and currently many drug discovery companies are specifically offering these services to pharmaceutical companies.

Europe is the second largest region in the drug discovery services market
The drug discovery services market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). After North America, Europe is the second-largest regional pharmaceutical market globally. The research-based pharmaceutical industry can play a critical role in ensuring future competitiveness in an advancing global economy (Source: EFPIA). The development of new chemical and biological molecules, alongside increased R&D activities, will help drive the growth of the drug discovery services market in Europe.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, Latin America -10%, and Middle East and Africa – 5%

Prominent Players of the drug discovery services market are Laboratory Corporation of America Holdings (US), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US), WuXi AppTec (China), Eurofins Scientific SE (Germany), Evotec SE (Germany), Syngene International Limited (India), Curia Global Inc. (US), Dr. Reddy Laboratories Ltd. (Aurigene Discovery Technologies) (India), Pharmaron Beijing Co., Ltd. (China), Piramal Enterprises Limited (India)

Research Coverage:
This report provides a detailed picture of the drug discovery market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall drug discovery market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
 
The report provides insights on the following pointers:
• Analysis of key drivers (Growing R&D expenditure in pharma-biotech sector, Increasing drug R&D pipeline and rising reliance on outsourcing, Initiatives for research on rare diseases and orphan drugs, and High cost of in-house drug development), restraints (Stringent regulations governing drug discovery and animal usage), opportunities (Technological advancements and new drug discovery techniques, Rising demand for specialized testing services among end users, Patent expiries of key biologics, and High growth prospects in emerging markets), and challenges (Shortage of skilled personnel) influencing the growth of drug discovery services market.
• Service Development/Innovation: Detailed insights on newly launched services, and technological assessment of the drug discovery market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the drug discovery services market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Laboratory Corporation of America Holdings (US), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US), WuXi AppTec (China) among others in the drug discovery services market. The report also helps stakeholders understand the pulse of drug discovery services market and provides them information on key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.2.1 INCLUSIONS AND EXCLUSIONS 43
1.3 MARKET SCOPE 44
1.3.1 MARKETS COVERED 44
1.4 YEARS CONSIDERED 44
1.5 CURRENCY CONSIDERED 45
1.6 LIMITATIONS 45
1.7 STAKEHOLDERS 45
1.8 SUMMARY OF CHANGES 46
1.8.1 RECESSION IMPACT 46
2 RESEARCH METHODOLOGY 47
2.1 RESEARCH DATA 47
FIGURE 1 RESEARCH DESIGN 47
2.1.1 SECONDARY DATA 48
2.1.2 PRIMARY DATA 49
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES 49
2.2 MARKET ESTIMATION METHODOLOGY 50
FIGURE 3 DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 50
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 51
FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2022 52
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 53
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 53
2.3 MARKET GROWTH RATE PROJECTIONS 54
FIGURE 7 DRUG DISCOVERY SERVICES MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 55
FIGURE 8 DRUG DISCOVERY SERVICES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 55
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 56
FIGURE 9 DATA TRIANGULATION METHODOLOGY 56
2.5 RESEARCH ASSUMPTIONS 57
2.6 RISK ANALYSIS 57
2.7 RECESSION IMPACT ANALYSIS 57
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 58
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 58
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 58
3 EXECUTIVE SUMMARY 59
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 59
FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 60
FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 60
FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 61
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF DRUG DISCOVERY SERVICES MARKET, 2022 62
4 PREMIUM INSIGHTS 63
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 63
FIGURE 15 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH 63
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2022) 64
FIGURE 16 SMALL-MOLECULE DRUGS HELD LARGEST SHARE OF NORTH AMERICAN DRUG DISCOVERY MARKET IN 2022 64
4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2022) 64
FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 64
4.4 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65
FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023–2028 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
FIGURE 19 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
TABLE 4 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS 67
5.2.1 DRIVERS 67
5.2.1.1 Growing R&D expenditure in pharma-biotech sector 67
FIGURE 20 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 68
5.2.1.2 Increasing drug R&D pipeline and rising reliance on outsourcing 68
FIGURE 21 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2022 69
5.2.1.3 Initiatives for research on rare diseases and orphan drugs 69
FIGURE 22 NUMBER OF DRUGS GIVEN ORPHAN DRUG STATUS (2013–2021) 70
5.2.1.4 High cost of in-house drug development 70
FIGURE 23 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 71
5.2.2 RESTRAINTS 71
5.2.2.1 Stringent regulations governing drug discovery and animal usage 71
 
5.2.3 OPPORTUNITIES 72
5.2.3.1 Technological advancements and new drug discovery techniques 72
5.2.3.2 Rising demand for specialized testing services among end users 72
5.2.3.3 Patent expiries of key biologics 73
TABLE 5 US: BIOLOGICS GOING OFF-PATENT DURING 2023–2027 73
5.2.3.4 High growth prospects in emerging markets 74
5.2.4 CHALLENGES 74
5.2.4.1 Shortage of skilled personnel 74
5.2.5 MARKET TRENDS 75
5.2.5.1 Adoption of AI in drug discovery 75
5.2.5.2 Increased outsourcing to emerging Asian economies 76
5.2.5.3 CRO industry consolidation 77
TABLE 6 DRUG DISCOVERY SERVICES MARKET: PROMINENT ACQUISITIONS, 2023–2021 77
5.2.5.4 Integrated end-to-end R&D service offerings 78
5.3 RANGES/SCENARIOS 79
FIGURE 24 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON DRUG DISCOVERY SERVICES MARKET GROWTH 79
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 80
FIGURE 25 REVENUE SHIFT AND NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS 80
5.5 VALUE CHAIN ANALYSIS 81
FIGURE 26 VALUE CHAIN ANALYSIS OF DRUG DISCOVERY SERVICES MARKET: HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE 81
5.6 ECOSYSTEM ANALYSIS 82
FIGURE 27 ECOSYSTEM ANALYSIS: DRUG DISCOVERY SERVICES MARKET 82
TABLE 7 SUPPLY CHAIN ECOSYSTEM 83
5.7 TECHNOLOGY ANALYSIS 84
5.8 PRICING ANALYSIS 86
5.8.1 AVERAGE SELLING PRICE TREND ANALYSIS 86
TABLE 8 DRUG DISCOVERY AND DEVELOPMENT PROCESS & COST OVERVIEW (2018 VS 2022) 86
5.9 REGULATORY ANALYSIS 87
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
 
5.10 PORTER’S FIVE FORCES ANALYSIS 89
TABLE 13 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 89
5.10.1 THREAT OF NEW ENTRANTS 89
5.10.2 THREAT OF SUBSTITUTES 90
5.10.3 BARGAINING POWER OF BUYERS 90
5.10.4 BARGAINING POWER OF SUPPLIERS 90
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 90
5.11 KEY CONFERENCES & EVENTS, 2022–2023 91
TABLE 14 DRUG DISCOVERY SERVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 91
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DRUG DISCOVERY SERVICES 92
5.12.2 BUYING CRITERIA FOR DRUG DISCOVERY SERVICES 92
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 92
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 93
6.1 INTRODUCTION 94
TABLE 15 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 94
6.2 TARGET SELECTION 95
6.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 95
TABLE 16 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 17 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 18 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 19 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 20 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2021–2028 (USD MILLION) 97
6.3 TARGET VALIDATION 97
6.3.1 EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE TO PROMOTE MARKET GROWTH 97
TABLE 21 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 22 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 23 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 24 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 25 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 100
6.4 HIT-TO-LEAD IDENTIFICATION 100
6.4.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE 100
TABLE 26 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 27 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 28 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 29 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 30 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2021–2028 (USD MILLION) 103
6.5 LEAD OPTIMIZATION 103
6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION 103
TABLE 31 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 32 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 33 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 34 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 35 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 105
6.6 CANDIDATE VALIDATION 105
6.6.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES 105
TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 37 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 38 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 39 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 40 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 108
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 109
7.1 INTRODUCTION 110
TABLE 41 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
7.2 CHEMISTRY SERVICES 110
7.2.1 CHEMISTRY SERVICES TO DOMINATE SERVICE TYPE MARKET 110
TABLE 42 CHEMISTRY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 43 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 44 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 45 ASIA PACIFIC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 46 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
7.3 BIOLOGY SERVICES 112
7.3.1 RESTRICTIONS ON ANIMAL USAGE TO SLOW MARKET GROWTH 112
TABLE 47 BIOLOGY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 48 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 49 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 50 ASIA PACIFIC: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 51 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 116
8.1 INTRODUCTION 117
TABLE 52 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 117
8.2 SMALL-MOLECULE DRUGS 117
8.2.1 SMALL-MOLECULE DRUGS TO HOLD LARGEST MARKET SHARE 117
TABLE 53 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 54 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 55 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 56 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 57 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2021–2028 (USD MILLION) 120
8.3 BIOLOGICS 120
8.3.1 MARKET GROWTH OF BIOLOGICS & CHALLENGES ASSOCIATED WITH DISCOVERY TO DRIVE ADOPTION OF OUTSOURCING SERVICES 120
TABLE 58 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 59 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 60 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 61 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 62 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 123
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 124
9.1 INTRODUCTION 125
TABLE 63 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 125
9.2 ONCOLOGY 126
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH 126
FIGURE 30 NUMBER OF ONCOLOGY CLINICAL TRIALS, 2012–2022 (THOUSAND) 126
TABLE 64 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2022) 127
TABLE 65 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 66 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 67 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 68 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 69 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 129
9.3 INFECTIOUS DISEASES 129
9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 129
TABLE 70 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 71 NORTH AMERICA DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 72 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 73 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 74 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 132
9.4 CARDIOVASCULAR DISEASES 132
9.4.1 HIGH MORTALITY RATES PROMPTING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 132
TABLE 75 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (AS OF DECEMBER 2022) 132
TABLE 76 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 77 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 78 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 79 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 80 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 135
 
9.5 NEUROLOGICAL DISEASES 135
9.5.1 INCREASING INVESTMENTS IN R&D FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET 135
TABLE 81 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2022) 136
TABLE 82 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 83 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 84 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 85 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 86 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138
9.6 IMMUNOLOGICAL DISORDERS 138
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 138
TABLE 87 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022) 138
TABLE 88 DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 139
TABLE 89 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 90 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 91 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 92 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 140
9.7 ENDOCRINE & METABOLIC DISORDERS 140
9.7.1 INCREASING DIABETIC POPULATION TO BOOST MARKET 140
FIGURE 31 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 141
TABLE 93 DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 94 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 95 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 96 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 97 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 143
9.8 RESPIRATORY DISORDERS 143
9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH 143
TABLE 98 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS (2022) 144
TABLE 99 DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 100 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 101 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 102 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 103 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 146
9.9 DIGESTIVE SYSTEM DISEASES 146
9.9.1 RISING DISEASE INCIDENCE DUE TO LIFESTYLE AND DIETARY CHANGES TO PROPEL MARKET 146
TABLE 104 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2021–2028 (USD MILLION ) 147
TABLE 105 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 106 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 107 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 108 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 148
9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH 148
9.10.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO BOOST MARKET 148
TABLE 109 DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY REGION, 2021–2028 (USD MILLION) 149
TABLE 110 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 111 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 112 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 113 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR GENITOURINARY DISEASES & WOMEN’S HEALTH, BY COUNTRY, 2021–2028 (USD MILLION) 151
9.11 OTHER THERAPEUTIC AREAS 151
TABLE 114 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 115 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 116 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 117 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 118 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 154
 
10 DRUG DISCOVERY SERVICES MARKET, BY END USER 155
10.1 INTRODUCTION 156
TABLE 119 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 156
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 156
FIGURE 32 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011–2021 157
TABLE 120 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 121 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 122 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 123 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 124 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 159
10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE 159
TABLE 125 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 159
10.2.2 TIER 1 COMPANIES 159
10.2.2.1 High investing capacity to drive growth 159
TABLE 126 TOP PHARMA COMPANIES, BY REVENUE (2022) 160
TABLE 127 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2021–2028 (USD MILLION) 160
TABLE 128 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 129 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 130 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 131 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 162
10.2.3 TIER 2 COMPANIES 162
10.2.3.1 Limited investment capacity to slow market growth 162
TABLE 132 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2021–2028 (USD MILLION) 162
TABLE 133 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 134 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 135 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 136 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 164
 
10.2.4 TIER 3 COMPANIES 164
10.2.4.1 Insufficient technical advantages to restrain growth 164
TABLE 137 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 138 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 139 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 140 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 141 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 166
10.3 ACADEMIC INSTITUTES 166
10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT 166
TABLE 142 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 167
TABLE 143 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 144 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 145 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 146 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 168
10.4 OTHER END USERS 168
TABLE 147 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 169
TABLE 148 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 149 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 150 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 151 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 171
11 DRUG DISCOVERY SERVICES MARKET, BY REGION 172
11.1 INTRODUCTION 173
TABLE 152 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 173
11.2 NORTH AMERICA 174
FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT (2022) 175
TABLE 153 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 154 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 176
TABLE 155 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 156 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 177
TABLE 157 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 177
TABLE 158 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 178
TABLE 159 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 178
11.2.1 US 178
11.2.1.1 US to dominate North American market 178
FIGURE 34 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) 179
TABLE 160 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 179
TABLE 161 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 162 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 180
TABLE 163 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 181
TABLE 164 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 181
TABLE 165 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 182
11.2.2 CANADA 182
11.2.2.1 Growing preference to conduct clinical trials in Canada to support market growth 182
TABLE 166 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 183
TABLE 167 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 168 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 183
TABLE 169 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 184
TABLE 170 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 184
TABLE 171 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 185
11.2.3 NORTH AMERICA: RECESSION IMPACT 185
11.3 EUROPE 186
TABLE 172 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 173 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 187
TABLE 174 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 175 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 187
TABLE 176 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 188
TABLE 177 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 188
TABLE 178 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 189
11.3.1 GERMANY 189
11.3.1.1 Germany to hold largest share of European market 189
TABLE 179 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 190
TABLE 180 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 181 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 190
TABLE 182 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 191
TABLE 183 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 191
TABLE 184 GERMANY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 192
11.3.2 UK 192
11.3.2.1 Government-private sector collaborations to boost market 192
TABLE 185 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 193
TABLE 186 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 187 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 193
TABLE 188 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 194
TABLE 189 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 194
TABLE 190 UK: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 195
11.3.3 FRANCE 195
11.3.3.1 Growing number of oncology research projects to propel market 195
TABLE 191 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 196
TABLE 192 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 193 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 196
TABLE 194 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 197
TABLE 195 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 197
TABLE 196 FRANCE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 198
11.3.4 ITALY 198
11.3.4.1 High number of clinical trials and low drug approval time to augment market 198
TABLE 197 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022) 199
TABLE 198 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 199
TABLE 199 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 199
TABLE 200 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 200
TABLE 201 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 200
TABLE 202 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 201
TABLE 203 ITALY: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 201
11.3.5 SPAIN 201
11.3.5.1 Short study start-up times and rising R&D expenditure to augment market 201
TABLE 204 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 202
TABLE 205 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 206 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 203
TABLE 207 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 203
TABLE 208 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 204
TABLE 209 SPAIN: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 204
11.3.6 REST OF EUROPE 204
TABLE 210 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2021–2028 (USD MILLION) 205
TABLE 211 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 212 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2021–2028 (USD MILLION) 206
TABLE 213 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 207
TABLE 214 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 207
TABLE 215 REST OF EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2021–2028 (USD MILLION) 208
11.3.7 EUROPE: RECESSION IMPACT 208